CAMBRIDGE, MA-(CRWENEWSWIRE) Nov/30/2009- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), a biopharmaceutical company discovering and developing targeted therapeutic and imaging radiopharmaceuticals primarily for use in oncology, today announced that at a recently held meeting, the Company’s Board of Directors determined to reduce its size from 11 to nine members. In conjunction with this decision, Dr. Anthony F. Martin informed the Board that he would resign as a director and a member of all of the Board Committees he currently serves, effective as of December 31, 2009, and Dr. Harry Stylli notified the Board that he would not stand for re-election at the forthcoming annual meeting of shareholders in May 2010 and would resign as a director and a member of all of the Board Committees he currently serves, effective as of the date of annual meeting. Both directors cited personal reasons and other professional commitments for their decisions.

“We appreciate the valuable and long-term contributions of Dr. Martin and Dr. Stylli to our Board and wish them the best in their future endeavors,” said Joseph M. Limber, Chairman of the Board.

“We believe that a nine-person Board comprised of highly qualified and committed individuals will capably guide our Company forward in a focused and efficient manner, as we advance and commercialize our development-stage pipeline and technologies,” commented Daniel L. Peters, President and CEO of Molecular Insight Pharmaceuticals, Inc.

About Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals is a clinical-stage biopharmaceutical company and pioneer in the emerging field of molecular medicine. The Company is focused on the discovery and development of targeted therapeutic and imaging radiopharmaceuticals, primarily for use in oncology. Molecular Insight has five clinical-stage candidates in development. For further information on Molecular Insight Pharmaceuticals, please visit www.molecularinsight.com.

Forward-Looking Statements

Statements in this release that are not strictly historical in nature constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our corporate strategy and expected function and role of our Board. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Molecular Insight to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; difficulties or delays in obtaining financing and generating the revenue as anticipated; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission (SEC). The Company’s SEC filings are available through the SEC’s Electronic Data Gathering Analysis and Retrieval system (EDGAR) at http://www.sec.gov/. Press releases for Molecular Insight Pharmaceuticals, Inc. are available on our website: http://www.molecularinsight.com/. All forward-looking statements are qualified in their entirety by this cautionary statement, and Molecular Insight undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
Contact:

Investors

Chuck Abdalian
Chief Financial Officer
(617) 871-6618
cabdalian@molecularinsight.com

Media

Martin A. Reynolds
Manager
Corporate Communications
(617) 871-6734
mreynolds@molecularinsight.com

Susan Pietropaolo
BCC Partners
(201) 923-2049
spietropaolo@bccpartners.com

SOURCE: Molecular Insight Pharmaceuticals, Inc.

CRWENewswire tracks and announces stocks daily and is pleased to offer its Stock Alerts. Investors can receive FREE Stock Alerts by visiting http://www.crwenewswire.com/signup

About CRWENewswire.com

CRWENewswire.com is an independent electronic informative online financial news publication company dedicated in providing company associates, business and financial professionals with economic and investment information, as well as stock highlights. CRWENewswire.com is a division of Crown Equity Holdings, Inc.

CRWENewswire.com is not a registered investment advisor or broker-dealer. CRWENewswire.com and Crown Equity Holdings, Inc., (CRWE) affiliates, officers, directors, contractors and employees, including may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com, and/or Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) Rule 17B requires disclosure of payment for investor relations